Portal de Periódicos da CAPES

Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines

2021; Massachusetts Medical Society; Volume: 385; Issue: 4 Linguagem: Inglês

10.1056/nejmoa2107058

1533-4406

Mark G. Thompson, Jefferey L. Burgess, Allison L. Naleway, Harmony L. Tyner, Sarang K. Yoon, Jennifer K. Meece, Lauren E.W. Olsho, Alberto J. Cabán-Martinez, Ashley Fowlkes, Karen Lutrick, Holly C. Groom, Kayan Dunnigan, Marilyn J. Odean, Kurt T. Hegmann, Elisha Stefanski, Laura Edwards, Natasha Schaefer Solle, Lauren Grant, Katherine Ellingson, Jennifer L. Kuntz, Tnelda Zunie, Matthew S. Thiese, Lynn Ivacic, Meredith G. Wesley, Julie Mayo Lamberte, Xiaoxiao Sun, Michael Smith, Andrew L. Phillips, Kimberly Groover, Young M. Yoo, Joseph Gerald, Rachel T. Brown, Meghan K. Herring, Gregory Joseph, Shawn C. Beitel, Tyler Morrill, Josephine Mak, Patrick Rivers, Brandon Poe, Brian Lynch, Yingtao Zhou, Jing Zhang, Anna Kelleher, Yan Li, Monica Dickerson, E. W. Hanson, Kyley Guenther, Suxiang Tong, Allen C. Bateman, Erik Reisdorf, John Barnes, Eduardo Azziz‐Baumgartner, Danielle Rentz Hunt, Melissa Arvay, Preeta K. Kutty, Alicia M. Fry, Manjusha Gaglani,

Viral gastroenteritis research and epidemiology

Information is limited regarding the effectiveness of the two-dose messenger RNA (mRNA) vaccines BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) in preventing infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and in attenuating coronavirus disease 2019 (Covid-19) when administered in real-world conditions.